NASDAQ
64.36USD
+3.07 (+5.01%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.8B
P/E
—
EPS
—
Beta
0.50
52W range
44.675-85.25
Day range
57.63–66.24
Open
57.63
Prev close
61.29
Volume
287.5K
Avg volume
971K
Dividend
0.00
IPO
2020-10-16
https://www.reuters.com/legal/litigation/tarsus-expand-eye-disease-pipeline-with-up-800-million-alkeus-acquisition-2026-08-06/ · 8/6/2026+0.60
https://www.marketbeat.com/instant-alerts/tarsus-pharmaceuticals-enters-retina-market-with-irenix-deal-adds-irx-101-to-pipeline-2026-07-11/ · 7/11/2026+0.80
https://seekingalpha.com/article/4920782-tarsus-pharmaceuticals-inc-tars-m-and-a-call-transcript · 7/9/2026+0.00
https://seekingalpha.com/article/4903501-tarsus-pharmaceuticals-inc-tars-presents-at-bank-of-america-global-healthcare-conference-2026 · 5/13/2026+0.00
https://www.globenewswire.com/news-release/2026/05/06/3289329/0/en/tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achievements.html · 5/6/2026
https://seekingalpha.com/article/4890407-tarsus-pharmaceuticals-stock-marketing-spend-bears-fruit-pipeline-progresses · 4/14/2026+0.80
https://www.globenewswire.com/news-release/2026/03/23/3260373/0/en/TP-03-lotilaner-ophthalmic-solution-0-25-Now-Approved-in-China-for-the-Treatment-of-Demodex-Blepharitis-Triggering-a-15M-Milestone-Payment-to-Tarsus.html · 3/23/2026+1.00
https://www.defenseworld.net/2026/03/22/insider-selling-tarsus-pharmaceuticals-nasdaqtars-insider-sells-279658-00-in-stock.html · 3/22/2026-0.20
https://www.defenseworld.net/2026/03/22/tarsus-pharmaceuticals-nasdaqtars-insider-sells-279693-18-in-stock.html · 3/22/2026-0.10
https://www.defenseworld.net/2026/03/15/ally-bridge-group-ny-llc-decreases-stake-in-tarsus-pharmaceuticals-inc-tars.html · 3/15/2026-0.20
https://www.defenseworld.net/2026/03/08/citigroup-inc-increases-position-in-tarsus-pharmaceuticals-inc-tars.html · 3/8/2026+0.40
https://www.zacks.com/stock/news/2873904/tarsus-pharmaceuticals-inc-tars-reports-q4-loss-beats-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2873904 · 2/24/2026-0.20
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
